Tarceva monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.

Results from two, multicenter, placebo-controlled, randomized, Phase III trials conducted in first-line patients with locally advanced or metastatic NSCLC showed no clinical benefit with the concurrent administration of Tarceva with platinum-based chemotherapy [carboplatin and paclitaxel or gemcitabine and cisplatin] and its use is not recommended in that setting.

This section is intended to help you when considering treatment options such as Tarceva (erlotinib) for Non-Small Cell Lung Cancer (NSCLC).

About Tarceva

Read about Tarceva as a targeted treatment.

Possible Benefits of Tarceva

Tarceva is convenient to use as a once-a-day pill and, based on clinical trials, does not have some of the side effects of traditional chemotherapy.

Preparing to Meet With Your Doctor

Answer some questions to help determine if you are a candidate for Tarceva, and find a printable list of useful questions to ask your physician.

Tarceva Clinical Trial Information

Learn about cancer treatment studies, the different types of clinical trials, and how the key trial of Tarceva was conducted. Also get useful information if you're interested in participating in a study.